Cerity Partners
KNSA icon

Cerity Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cerity Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59M Sell
40,488
-3,224
-7% -$167K ﹤0.01% 1448
2026
Q1 		$2.1M Buy
43,712
+493
+1% +$21.8K ﹤0.01% 1462
2025
Q4 		$1.78M Buy
43,219
+183
+0.4% +$7.34K ﹤0.01% 1418
2025
Q3 		$1.67M Buy
43,036
+1,132
+3% +$36.8K ﹤0.01% 1369
2025
Q2 		$1.16M Buy
41,904
+1,196
+3% +$30.4K ﹤0.01% 1452
2025
Q1 		$904K Buy
40,708
+12,110
+42% +$249K ﹤0.01% 1476
2024
Q4 		$713K Sell
28,598
-4,786
-14% -$109K ﹤0.01% 1575
2024
Q3 		$834K Buy
+33,384
New +$813K ﹤0.01% 1490
2024
Q2 		– Sell
-29,683
Closed -$586K – 2316
2024
Q1 		$586K Buy
+29,683
New +$580K ﹤0.01% 1528
2021
Q3 		– Sell
-25,000
Closed -$348K – 706
2021
Q2 		$348K Hold
25,000
– – 0.01% 542
2021
Q1 		$463K Buy
+25,000
New +$511K 0.01% 464

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Cerity Partners's KNSA Position: Q2 2026 in Review

Cerity Partners reduced its Kiniksa Pharmaceuticals (KNSA) stake by 7.4% in Q2 2026, selling an estimated $167K and leaving 40,488 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1448.

Cerity Partners first reported a position in KNSA in Q1 2021 and has held it in 11 quarters since. 249 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Cerity Partners held 40,488 shares of Kiniksa Pharmaceuticals worth $2.59M as of Q2 2026.
  • Cerity Partners sold 3,224 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $167K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1448 holding.
  • Cerity Partners first reported a position in Kiniksa Pharmaceuticals in Q1 2021 and has held it in 11 quarters since.
  • 249 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.